Overview

ADI-PEG in Patients With Metastatic Melanoma

Status:
Completed

Trial end date:
2003-08-01

Target enrollment:

Participant gender:

Summary

This is a study to determine the safety and toxicity of increasing doses of arginine deiminase combined to polyethylene glycol (ADI-PEG) in patients with nonresectable metastatic melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

FDA Office of Orphan Products Development